Oncology Business Management | Specialty

Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

Treating Unresectable HCC in the Community

February 1st 2020

Sequencing With I-O Combinations in Unresectable HCC

February 1st 2020

Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020

IMbrave150 in Unresectable HCC

February 1st 2020

Immunotherapy in Unresectable HCC

February 1st 2020

Challenges With Novel Treatment Strategies

February 1st 2020

The COSMIC-312 Phase III and Other Notable Trials

February 1st 2020

IMbrave150 Phase III Design, Results, and Practical Implications

February 1st 2020

The Impact of Liver Pathobiology on HCC Treatment Approach

February 1st 2020

Dr. Marshall on Physician Burnout in Oncology

January 31st 2020

John L. Marshall, MD, discusses physician burnout in oncology.

Practices Make Surprise Decision on OCM Risk

January 30th 2020

Many practices enrolled in the Oncology Care Model were expected to drop out of the value-based model rather than take on 2-sided risk, which would entail upside and downside financial exposure.

Germline Testing Holds Promise But Demands a Cautious Approach

January 23rd 2020

A better understanding of how unique germline variants affect the metabolism or elimination of individual agents or drug classes could lead to a truly revolutionary change in the way cancer is treated.

Studies of Harassment in Oncologic Gynecology Add Fuel to Reform Efforts

January 18th 2020

Anecdotes of gender inequality and sexual harassment abound among gynecologic oncologists, but until recently, there had been no study to measure the problem in this profession. Findings reported in June 2019 suggesting that high numbers of men and women in this field were subject to sexual harassment were no surprise to investigators. Instead, they have strengthened national gender discrimination and sexual harassment reform efforts in oncologic gynecology.

Patient Input Should Inform Oncology Trial Design and Interpretation

January 13th 2020

Even the most basic investigation into fundamental mechanisms of the development and progression of cancer in an in vitro system may generate data that, ultimately, prove vital to developing new approaches to prevent, diagnose, and treat malignant disease.

Advanced Practitioners Improve Oncology Care Value

January 12th 2020

The aging of the baby boomer population and the growing number of cancer survivors have created a huge demand for oncology treatment services. Centers for Medicare & Medicaid Services has compounded the need by ratcheting up standards for value-based care. To handle these additional needs, many oncology practices now turn to advanced practice providers, typically nurse practitioners or physician assistants, who are highly trained and capable of taking over many of the routine functions of the oncology clinic.

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020